The Essential Oil Derived from Perilla frutescens (L.) Britt. Attenuates Imiquimod-Induced Psoriasis-like Skin Lesions in BALB/c Mice

Molecules. 2022 May 7;27(9):2996. doi: 10.3390/molecules27092996.

Abstract

Psoriasis is reported to be a common chronic immune-mediated skin disease characterized by abnormal keratinocytes and cell proliferation. Perilla leaves are rich in essential oils, fatty acids, and flavonoids, which are recognized for their antioxidant and anti-inflammatory effects. In this study, the alleviating effect of essential oil (PO) extracted from Perilla frutescens stems and leaves on imiquimod (IMQ) -induced psoriasis-like lesions in BALB/c mice were investigated. Results showed that PO ameliorated psoriasis-like lesions in vivo, reduced the expression of lymphocyte antigen 6 complex locus G6D (Ly-6G), which is a marker of neutrophil activation, and inhibited the expression of inflammatory factors interleukin 1 (IL-1), interleukin 6 (IL-6), inducible nitric oxide synthase (iNOS), and cyclooxygenase 2 (COX2). In addition, PO significantly decreased the expression of cytokines such as IL-6, IL-1, interleukin 23 (IL-23), interleukin 17 (IL-17), and nuclear factor kappa-B (NF-κB). Furthermore, the down-regulation of mRNA levels of psoriasis-related pro-inflammatory cytokines, such as IL-17, interleukin 22 (IL-22), IL-23, interferon-α (IFN-α), and Interferon-γ (IFN-γ) was observed with the treatment of PO. All results show a concentration dependence of PO, with low concentrations showing the best results. These results suggest that PO effectively alleviated psoriasis-like skin lesions and down-regulated inflammatory responses, which indicates that PO could potentially be used for further studies on inflammation-related skin diseases such as psoriasis and for the treatment of psoriasis such as psoriasis natural plant essential oil resources.

Keywords: essential oil; imiquimod; inflammation; psoriasis.

MeSH terms

  • Animals
  • Cytokines / metabolism
  • Dermatitis* / pathology
  • Disease Models, Animal
  • Imiquimod / adverse effects
  • Interleukin-1
  • Interleukin-17
  • Interleukin-23
  • Interleukin-6 / pharmacology
  • Keratinocytes
  • Mice
  • Mice, Inbred BALB C
  • Oils, Volatile* / adverse effects
  • Perilla frutescens* / metabolism
  • Psoriasis* / chemically induced
  • Psoriasis* / drug therapy
  • Skin / metabolism

Substances

  • Cytokines
  • Interleukin-1
  • Interleukin-17
  • Interleukin-23
  • Interleukin-6
  • Oils, Volatile
  • Imiquimod

Grants and funding

Funding: This research was funded by National Natural Science Foundation of China (grant number 22178070) and Inner Mongolia Science and Technology Project (grant number 2021CG0029).